Abstract
The metallothionein content of ovarian tumours is considerably higher than that found in normal ovaries (greater than 100-fold differences in mean values, P less than 0.001). There was no difference between the metallothionein content of tumours from patients who had completed chemotherapy, usually with a regimen containing a platinum drug, and tumours from untreated patients. Similarly, the level of metallothionein was not influenced by response to therapy, age, stage, histology, or tumour cell differentiation state. These data do not support the hypothesis that metallothionein content is a major determinant of tumour sensitivity in ovarian cancer.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andrews P. A., Murphy M. P., Howell S. B. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol. 1987;19(2):149–154. doi: 10.1007/BF00254568. [DOI] [PubMed] [Google Scholar]
- Bakka A., Endresen L., Johnsen A. B., Edminson P. D., Rugstad H. E. Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein. Toxicol Appl Pharmacol. 1981 Nov;61(2):215–226. doi: 10.1016/0041-008x(81)90411-7. [DOI] [PubMed] [Google Scholar]
- Behrens B. C., Hamilton T. C., Masuda H., Grotzinger K. R., Whang-Peng J., Louie K. G., Knutsen T., McKoy W. M., Young R. C., Ozols R. F. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 1987 Jan 15;47(2):414–418. [PubMed] [Google Scholar]
- Endresen L., Schjerven L., Rugstad H. E. Tumours from a cell strain with a high content of metallothionein show enhanced resistance against cis-dichlorodiammineplatinum. Acta Pharmacol Toxicol (Copenh) 1984 Sep;55(3):183–187. doi: 10.1111/j.1600-0773.1984.tb02034.x. [DOI] [PubMed] [Google Scholar]
- Kaina B., Lohrer H., Karin M., Herrlich P. Overexpressed human metallothionein IIA gene protects Chinese hamster ovary cells from killing by alkylating agents. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2710–2714. doi: 10.1073/pnas.87.7.2710. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Karin M., Richards R. I. The human metallothionein gene family: structure and expression. Environ Health Perspect. 1984 Mar;54:111–115. doi: 10.1289/ehp.8454111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kelley S. L., Basu A., Teicher B. A., Hacker M. P., Hamer D. H., Lazo J. S. Overexpression of metallothionein confers resistance to anticancer drugs. Science. 1988 Sep 30;241(4874):1813–1815. doi: 10.1126/science.3175622. [DOI] [PubMed] [Google Scholar]
- Nash J. D., Young R. C. Gynecologic malignancies. Cancer Chemother Biol Response Modif. 1988;10:291–312. [PubMed] [Google Scholar]
- Patierno S. R., Pellis N. R., Evans R. M., Costa M. Application of a modified 203Hg binding assay for metallothionein. Life Sci. 1983 Apr 4;32(14):1629–1636. doi: 10.1016/0024-3205(83)90870-6. [DOI] [PubMed] [Google Scholar]
- Schilder R. J., Hall L., Monks A., Handel L. M., Fornace A. J., Jr, Ozols R. F., Fojo A. T., Hamilton T. C. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer. 1990 Mar 15;45(3):416–422. doi: 10.1002/ijc.2910450306. [DOI] [PubMed] [Google Scholar]
- Teicher B. A., Holden S. A., Kelley M. J., Shea T. C., Cucchi C. A., Rosowsky A., Henner W. D., Frei E., 3rd Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res. 1987 Jan 15;47(2):388–393. [PubMed] [Google Scholar]